Navigation Links
Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Date:1/17/2008

RIDGEFIELD, Conn., Jan. 17 /PRNewswire/ -- Boehringer Ingelheim announced today that enrollment is complete for the landmark RE-LY trial to evaluate the long-term efficacy and safety of investigational oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke and systemic embolism in patients with atrial fibrillation. RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) is the largest stroke prevention in atrial fibrillation trial conducted to date, with 18,114 patients, in 1,000 centers in 44 countries worldwide enrolled between December 2005 and December 2007. Currently, more than 10,000 patients have been treated for at least 6 months with final study results expected to be reported in early 2009.

The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.0-3.0) in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of stroke. Currently, the standard treatment to prevent stroke in these patients is the vitamin K antagonist, warfarin. It is estimated that warfarin is currently prescribed for only half of all eligible patients.

Dr. Salim Yusuf, Professor of Epidemiology and Cardiology and head of the study coordinating center at McMaster University in Hamilton, Canada, stated that: "Patient enrollment in RE-LY has exceeded our original expectations by far."

Atrial fibrillation is the most common sustained cardiac rhythm disturbance affecting six percent of individuals over the age of 65 and 10 percent of people over the age of 80. Atrial fibrillation is a leading risk factor for stroke and, despite warfarin sodium being available as an effective treatment option, atrial fibrillation still accounts for approximately 15 percent of all strokes.

Approximately 750,000 Americans suffer a stroke each year. More than 150,000 of these strokes are fatal, making it the third leading cause of death in the United States. Approxima
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...Neb., Dec. 4 Amber Pharmacy announ...creditation Commission for Health Care, Inc. (ACHC... years, Amber Pharmacy has provided comprehensive ...ique needs of specialized conditions. Amber Pharma...transplant programs. They work with over 170 trans...
(Date:12/4/2009)...AKE CITY, Dec. 4 Dynatro... signed a sole-source vendor agreement to provide ...Physical Therapy with 65 clinics located in Tennes...d the sole-source supplier to Benchmark Physical T...esident of sales and marketing at Dynatronics. "Be...
(Date:12/4/2009)..., WASHINGTON, Dec. 4 /PRNewswire-USNewswire/ ...eport published by the Pharmaceutical Research a...fies 97 new drugs and vaccines in development for ...ort found that the 97 products in development inc...e either in human clinical trials or awaiting appr...
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 1FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 3FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 4FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 5FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 6FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 7U S Census Bureau Daily Feature for July 21 52174 1UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 1UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 2UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 3UPDATE 3A US Oncology Research Network Participates in Phase III Follow up Study to BiPars Investigational Cancer Drug BSI 201 4753 4
...07 /CNW/ - Protox,Therapeutics Inc. (TSX-V:PRX) to...Phase 1 clinical trial evaluating ,PRX302 in patie...owing radiation failure. The trial results indica...ws promising signs,of therapeutic activity followi...The completion of the PRX302 Phase 1 trial is enco...
...P-233) Ability to Clear Brain,Plaque and Empower R...o ,Proof of Concept, Study Proposes Direct Correla...ry Recovery , LAS VEGAS, July 10, 2007 (PRIME NEWS..., a developer of innovative drugs,is pleased to a...ficacy in its ability to dramatically decrease bet...
Other Medicine Technology:Protox Announces Positive Clinical Data from Prostate Cancer Study 2Protox Announces Positive Clinical Data from Prostate Cancer Study 3Protox Announces Positive Clinical Data from Prostate Cancer Study 4Protox Announces Positive Clinical Data from Prostate Cancer Study 5Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 2Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 3
(Date:12/4/2009)...c. 4 While Congress deb...th care costs, Leapfrog,s purchaser members point ...ering the best quality care in the nation while at...our urban, eight children,s and three rural hospit...ased on results from The Leapfrog Hospital Survey....
(Date:12/4/2009)...tists at Johns Hopkins publishing in the December ...e by a gene called "Twist" may be the proverbial r... that drive aggressive, metastatic breast cancer f...ent work suggesting that it is a relatively rare s... breast cancer, scientists have surmised that this...
(Date:12/4/2009)...ntal tourism is a phenomenon that was started by p...high price of dental work in the US, Canada, and o...ental care, people have found that Mexican Dental ...tination. , (PRWEB) Decem...an 6 years, Mexican Dental Vacation is seeing thei...
(Date:12/4/2009)...RNewswire/ -- Substantial progress has been made o...s ability to diagnose and treat epilepsy and its c...ement has not reached most of the 50 million peopl...hree million people in the United States who have ...er, M.D., president of the American Epilepsy Socie...
(Date:12/4/2009)...ering drugs known as statins are among the most pr...researchers at Fred Hutchinson Cancer Research Cen...ransplant patients from one of the most serious co...ft-versus-host disease, or GVHD. The findings are ...l Blood . , In a retrospective study of 567 pati...
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2
...r osteoarthritis of the knee back to the future.Th...helps relieve pain and other symptoms better than ...ation of leeches to treat pain is an ancient medic...s, such as in treating postoperative complications...
...by viral cold are common in preschoolers. These at... frequency disappears by school age. //The current...eroids at the first sign of an attack. But whether...atory symptoms or the need for hospital admission....
...diagnosed with type 2 diabetes and now research sh...eater risk for a heart attack and stroke. //Specif...d with type 2 diabetes are 14-times more likely to...oing to get heart disease, heart attacks and strok...
...soon be fighting a losing battle. Scientists from ...uccessfully stopped the tuberculosis pathogen's ab...cally hides out in the immune system in a cell cal...s TB. Thus far, all of the research has been done ...
...on condition that can be fatal. It is defined as a...lly due to a blood clot, //which blocks a coronary...for a pulmonary embolism, a new study shows a new ...t 600,000 Americans develop a pulmonary embolism a...
...eir mouths. But as children get older, they become...y if they have not tried it before. Green veget... scientists say thousands of years ago toxins in p...ous of certain food types as youngsters. Resear...
Other Medicine News:
Surgiflex® WAVE XP™ Handpiece and Pump, without probe shaft
Surgiflex® WAVE XP™ Handpiece and Pump
SUCTION IRRIGATION: StrykeFlow PS
SUCTION IRRIGATION: StrykeFlow 2
Medicine Products: